tert-butyl N-[4-[(5-cyanopyridine-2-carbonyl)amino]-9,9-dimethyl-8,12,14-trioxa-16-azapentacyclo[8.6.0.01,13.02,7.010,13]hexadeca-2(7),3,5,15-tetraen-15-yl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: tert-butyl N-[4-[(5-cyanopyridine-2-carbonyl)amino]-9,9-dimethyl-8,12,14-trioxa-16-azapentacyclo[8.6.0.01,13.02,7.010,13]hexadeca-2(7),3,5,15-tetraen-15-yl]carbamate
• 化学式: C₂₆H₂₅N₅O₆
• 分子量: 503.5
• InChiKey: ATUKPFJPPYNKAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] CHROMANE COMPOUNDS<br/>[FR] COMPOSÉS DE CHROMANE
  申请人：ASTELLAS PHARMA INC

  公开号：WO2013181202A2

  公开（公告）日：2013-12-05

  The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β -amyloid precursor protein, and/or β -amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.